tirzepatide for obesity fda approval Zepbound (tirzepatide) injection, the first and only treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly GROUNDBREAKING UPDATE! FDA has approved
Description
Application and Indication Analysis GLP-1 Weight Loss Drug Market by Indication: Obesity Management Commands 61.4% of Revenue While Cardiovascular and Metabolic Indications Drive Premium Expansion GLP-1 Drug Market Revenue Share, CAGR, and Key Clinical Evidence by Application 2026 Obesity and chronic weight management represents the largest GLP-1 drug market application at 61.4% revenue share in 2026
Sources Cleveland Clinic

Next, add a new needle to the pen

A microdosing approach to tirzepatide might start at 10 units (1mg) for the first two weeks before moving to 15 units (1.5mg) and then 20 units (2mg)

Gastrointestinal safety of semaglutide and tirzepatide versus placebo in obese individuals without diabetes: A systematic review and meta analysis
